-+ 0.00%
-+ 0.00%
-+ 0.00%

Lavipharm nine-month adjusted EBITDA from continuing operations rises 13% to €10.71 million

PUBT·11/19/2026 15:35:13
Lavipharm nine-month adjusted EBITDA from continuing operations rises 13% to €10.71 million
  • Lavipharm’s nine-month 2026 adjusted EBITDA from continuing operations rose 13% to €10.71 million.
  • Durogesic sales launched in France on September 30, 2026, expanding the group’s export portfolio.
  • The product is expanding into additional countries as marketing authorizations continue to be secured.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lavipharm SA published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.